Company Overview
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.37.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +489.46% |
| 6 Months: | +182.34% |
| 3 Months: | +29.21% |
| 1 Month: | +23.98% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)59.05 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ORKA Oruka Therapeutics, Inc. R2K | 86.65 | -44.90 | $5.23B | 0.00% | -25.79% | -27.31% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | - | - | - | - | - |
| Operating Income | -2.72M | -2.82M | -3.67M | -3.94M | -4.71M | -4.38M | -5.56M | -4.47M | - | -2.77M | -2.16M | -1.66M | - | -1.78M | -1.51M | -1.25M | - | -1.34M | -1.31M | -1.99M | - | -4.10M | -4.84M | -4.72M | - | -3.28M | -3.22M | -2.55M | - | -1.80M | -1.97M | -1.94M | - | -2.48M | -21.49M | -29.45M | -25.09M | -28.43M | -34.10M | -36.43M |
| Net Income | -2.72M | -2.81M | -3.65M | -3.89M | -4.66M | -4.34M | -5.52M | -4.43M | -4.20M | -2.73M | -2.12M | -1.59M | -1.49M | -1.66M | -1.44M | -1.16M | -1.23M | -1.32M | -1.30M | -1.99M | -5.12M | -4.10M | -4.83M | -4.71M | -5.68M | -3.27M | -3.15M | -2.33M | -1.17M | -1.35M | -1.48M | -1.42M | -1.09M | -2.01M | -22.24M | -28.62M | -21.00M | -24.57M | -30.28M | -31.82M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.34 | -0.33 | - | -0.23 | -0.22 | -0.16 | - | -0.09 | -0.10 | -0.10 | - | -0.14 | -6.96 | -1.46 | -0.40 | -0.46 | - | - |
| R&D Expense | 1.75M | 1.72M | 2.59M | 2.91M | 3.72M | 3.25M | 4.51M | 3.49M | - | 1.72M | 1.15M | 740.00K | - | 662.00K | 440.00K | 347.00K | - | 365.00K | 372.00K | 1.05M | - | 2.88M | 3.58M | 3.44M | - | 2.18M | 1.49M | 1.02M | - | 390.00K | 254.00K | 322.00K | - | 165.00K | 18.67M | 25.69M | 19.93M | 24.09M | 28.99M | 29.14M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - |
| Operating Income | - | - | - | - | - | - | -9.18M | -7.36M | -4.32M | -6.94M | -9.69M | -11.46M | -16.61M | -18.71M | -8.12M | -5.81M | -9.77M | -19.34M | -10.60M | -7.30M | -88.12M | -122.05M |
| Net Income | -511.00K | -1.46M | -5.24M | -13.99M | -19.43M | -9.14M | -8.42M | -5.36M | -4.32M | -6.94M | -9.69M | -11.45M | -16.44M | -18.49M | -7.93M | -5.48M | -9.74M | -19.32M | -9.93M | -5.34M | -83.72M | -105.43M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.39 | -0.69 | -0.37 | -3.87 | - |
| R&D Expense | - | - | - | - | - | - | 3.11M | 2.31M | 1.09M | 2.93M | 5.62M | 7.06M | 12.35M | 14.08M | 4.24M | 1.83M | 4.99M | 13.83M | 4.75M | 1.01M | 75.06M | 100.64M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Feb 2024 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | 8.16M | 6.50M | 3.21M | 17.08M | 16.13M | 39.57M | 24.63M | 12.37M | 6.83M | 8.54M | 50.43M | 54.92M | 43.09M | 37.86M | 1.00K | 396.02M | 488.62M |
| Total Equity | -115.00K | -619.00K | -678.00K | -5.74M | -19.69M | -38.18M | 7.41M | 6.77M | 5.73M | 2.91M | 15.58M | 14.74M | 38.07M | 22.19M | 10.28M | 6.03M | 7.61M | 46.52M | 51.04M | 41.67M | 37.02M | 1.00K | 382.22M | 471.93M |
| Cash & Equivalents | - | - | - | - | - | - | 7.76M | 7.03M | 5.94M | 2.92M | 16.76M | 15.35M | 38.80M | 7.40M | 8.70M | 6.61M | 8.36M | 49.07M | 53.36M | 42.45M | 37.43M | - | 61.58M | 46.94M |
| Total Liabilities | - | - | - | - | - | - | - | 1.39M | 770.00K | 305.00K | 1.50M | 1.39M | 1.50M | 2.44M | 2.09M | 793.00K | 926.00K | 3.91M | 3.88M | 1.41M | 841.00K | - | 13.80M | 16.69M |
| Current Liabilities | - | - | - | - | - | - | - | 1.19M | 754.00K | 305.00K | 1.50M | 1.39M | 1.50M | 2.40M | 2.07M | 793.00K | 926.00K | 3.50M | 3.50M | 1.13M | 637.00K | - | 13.04M | 15.37M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -8.32M | -6.96M | -4.08M | -5.29M | - | - | - | -17.47M | -8.24M | -4.80M | -7.72M | -18.76M | -10.91M | -5.01M | -57.84M | -88.21M |
| Investing Cash Flow | 265.00K | 2.01M | - | -32.00K | - | - | - | 12.93M | 3.05M | -4.00K | -19.00K | -43.00K | -2.00K | 0 | -330.13M | -96.75M |
| Financing Cash Flow | 7.32M | 3.87M | 1.05M | 19.16M | - | - | - | 5.85M | 3.10M | 6.56M | 48.45M | 23.09M | 0 | 0 | 449.54M | 170.31M |
| Capital Expenditure | -4.00K | -19.00K | - | -32.00K | -19.00K | -11.00K | -12.00K | -3.00K | -4.00K | -4.00K | -19.00K | -43.00K | -2.00K | -0 | -189.00K | -209.00K |
| Free Cash Flow | -8.33M | -6.98M | - | -5.32M | - | - | - | -17.48M | -8.25M | -4.80M | -7.74M | -18.80M | -10.91M | -5.01M | -58.03M | -88.42M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ROE % | 82.6% | 215.2% | 91.2% | 71.1% | 50.9% | -123.3% | -124.4% | -93.6% | -148.6% | -44.5% | -65.7% | -30.1% | -74.1% | -180.0% | -131.5% | -72.0% | -20.9% | -37.9% | -23.8% | -14.4% | -21.9% | -22.3% |
| ROCE % | - | - | - | - | - | - | -131.7% | -128.1% | -148.6% | -44.5% | -65.7% | -30.1% | -74.7% | -181.8% | -134.6% | -76.4% | -20.8% | -37.6% | -25.3% | -19.6% | -23.0% | -25.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 12.32% | 7.43M | $641.96M |
| 2 | Venrock Adviser, LLC | 6.88% | 4.15M | $358.36M |
| 3 | Fairmount Funds Management LLC | 6.14% | 3.71M | $320.08M |
| 4 | Blackrock Inc. | 5.85% | 3.53M | $304.69M |
| 5 | Viking Global Investors, L.P. | 4.42% | 2.67M | $230.36M |
| 6 | Paradigm Biocapital Advisors LP | 3.85% | 2.32M | $200.44M |
| 7 | RTW Investments LP | 3.41% | 2.06M | $177.79M |
| 8 | Deep Track Capital, Lp | 3.37% | 2.03M | $175.72M |
| 9 | Vanguard Capital Management LLC | 3.08% | 1.86M | $160.64M |
| 10 | State Street Corporation | 2.68% | 1.61M | $139.38M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ORKA
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxPWi0tU3NOVC1Ga1ExcHNsZ0RoNE9wOG1yd1lqZVdJWmZmaXNWQkZNN3dvSUtoTUdQN2lWcW1Jd2N1SG0xU3djS0RBUEktRFd0VUtDV21hWVdYLVNpM3NiYVZNQV9Kd2d2NXdQekV3OTMtQi13UXZQc1Bzd00yNXpob2I3TG5TTm9VMU9sTW…
Discipline and Rules-Based Execution in ORKA Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxPbGdPNVBPSU4zalcxM25BalE0bkNRYXEtN2M0S3Z5Z00wcVR0d3pSRlQ1LTBPUVQwQTdiVkVwNm9YaEU4WlRRUTV4Y2MxV0d3UUE4eXpwY1Vxek9obDdSWDhjSmFxdWs0NmItOHFvR0hLMVF1V0RBdFpOeE5iNTVVb0NkQmIzOEZWWVpFYV…
Oruka Therapeutics CMO Joana Goncalves sells $603,937 in shares By Investing.com - Investing.com Canada
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNZkJMSU84dnlxQXpvcko0RzFOdXNKU0VaUWE4c0llUHE4RUpUcFNXYXc2Q2F0cTJnMEQ5VHV2VWRKYTFLUEdJMmNodEVhczlzdEJWSlRJMFc2TUhTbFViOXhYcGF2eldCcGRNbklScFF6Y04zTGpGSkdBc05QQzJ2Vkx4VGZkLWgwTXhjZX…
$ORKA stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPX2RpNklxQmljbnk2MUpIYkJxYk10c25Mdkgyd1VYdzBsTzdlTTIwNk1Ua2ppb2ZpSHp5S2dRVlk1V3ZSS3VmcWNKSkFoNUpXWVJ6eDcyTlYyZzZ6cGJqbkhjczZDNFhQaGhxWFJVN0tZeTAtZ290ZE45N0kyNG5RZERjR0xfWXB6YlRCTX…
How Investors May Respond To Oruka Therapeutics (ORKA) Russell Index Shift Toward Small-Cap Growth Benchmarks - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxNUURjSjhESGVzU3hCOXZSTTR2YTNQMExsR3Z0cjFaZlBiWUlPMTgwSGFZV083RndCcHROZHJhNmI1TnlWMVBNVmtxQjM2MkcwM1RBeGNMbUR4OVpLYmYzN0x4N2c0NVpSUnd0anlLQWVuOHBNclBrb29USG1qZ3pvMzZVMVUwX2toMGc3TG…
ORKA Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBRbVJUamh6R0JfNTU5N3hMN0xEUUJFQjZPWkd1RVlGdkxIRG50cXAwUTlYdDFMQzF4UWVOVFB5WlRPNkM5WXNmMjg3TGtRaGlPTlpBMnowWDRBVUczNHJQMWRRejBTdHBub1JVOWJOVVVFZTV2TzljMzZB?oc=5" target="_blank">ORK…
ORKA — Frequently Asked Questions
What is the current share price of Oruka Therapeutics, Inc. (ORKA)?
As of 2026-07-15 16:51 PDT, Oruka Therapeutics, Inc. (ORKA) trades at $86.65 on NasdaqGM. Its 52-week range is $13.05 to $95.17.
What is the market capitalisation of ORKA?
Oruka Therapeutics, Inc. (ORKA) has a market capitalisation of $5.23B on NasdaqGM.
What is the P/E ratio of ORKA?
ORKA trades at a trailing price-to-earnings (P/E) ratio of -44.90. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 8.96.
What is the return on equity (ROE) of ORKA?
ORKA has a return on equity (ROE) of -27.31%. Its return on capital employed (ROCE) is -25.79%.
Is ORKA a good stock to buy?
This page provides a data-driven analysis of Oruka Therapeutics, Inc. (ORKA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.